secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001104659-25-026391
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents reschedules earnings call to March 31; reaffirms Q4 product revenue $9.0-$9.2M (22-25% growth)
--------------------------------------------------------------------------------

- Earnings call rescheduled to March 31, 2025 at 4:30 PM ET; annual audit still in progress.
- Q4 product revenue expected $9.0-$9.2M (+22-25% YoY); full-year product revenue $35.4-$35.6M (+14% YoY).
- Q4 product gross margin ~70%, vs 61% prior quarter and 72% prior year.
- Pro-forma cash balance at Dec 31, 2024 ~$17.0M (unrestricted $15.5M); net Q4 cash burn ~$2.5M.
- DrugSorb-ATR marketing applications under FDA and Health Canada review; regulatory decisions expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925026391/0001104659-25-026391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925026391/tm259948d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-026391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer